Nextcure provides business update and reports full year 2022 financial results

Beltsville, md., march 02, 2023 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided a business update and reported full year 2022 financial results.

NXTC Ratings Summary

NXTC Quant Ranking